New OHAD blog on CLVS (& FMI) http://www.orf-blog.com/clovis-oncology-the-more-you-ignore-me-the-closer-i-get/ Portfolio update Following the positive results for rociletinib and rucaparib, we are adding a second position in Clovis and a third position in Foundation Medicine. We are also initiating a position in Conatus (CNAT).